Preclinical biopharma
Insulin-producing beta cell regeneration as a curative approach for diabetes
Novapeutics is developing an oral, first-in-class small molecule approach designed to restore pancreatic islet function by regenerating the body’s own insulin-producing beta cells.
38.4MAmericans living with diabetes in 2021.
830MPeople living with diabetes globally by 2022.
OralSmall-molecule regenerative therapeutic strategy.
Executive Summary
A disease-modifying path for patients whose beta-cell function has declined.
Diabetes prevalence has increased dramatically over the past century, while most therapies still focus on glucose management. Novapeutics is built around pancreatic islet restoration: regenerating insulin-producing beta cells so the pancreas can recover function.
Platform
The same Novapeutics visual story, redesigned into a clearer marketing flow.
Candidate
Potent iMen small-molecule leads designed for oral beta-cell regeneration.
Mechanism
Selective interruption of menin-MLL signaling to support beta-cell regeneration.
Molecular Target
A first-in-class diabetes target informed by menin structural biology.
Drug Discovery
Structure-based design and high-throughput screening for partner-ready development.
Preclinical evidence
Regeneration signals across pancreatic islet mass, insulin response, and glucose normalization.
Novapeutics’ pitch materials describe iMen effects in NOD and DIO mouse models, including restored pancreatic islet mass, improved glucose tolerance, increased insulin response, and human beta-cell regeneration signals.
Commercial thesis
A regenerative oral therapy could shift the diabetes treatment curve.
Existing oral drugs are commonly used in earlier disease stages, while mid to advanced patients move toward injectable GLP-1 agonists and insulin. Novapeutics is positioning an oral regenerative approach for patients whose beta-cell function has declined.
The opportunity centers on disease modification, oral delivery, and a therapeutic profile that could be attractive to diabetes-focused pharmaceutical partners.
Invest in Cure
Bring a beta-cell regeneration therapeutic closer to the clinic.
Novapeutics is seeking investors and development partners to advance its preclinical diabetes program, medicinal chemistry path, and IND-enabling studies.
Contact us
Frank Leu, Ph.D.
Co-Founder and Manager